

Special Issue

Breast Cancer: Molecular and Translational Aspects on Carcinogenesis and Treatments

Message from the Guest Editor

Breast cancer treatment is increasingly guided by molecular profiling of individual tumors. Currently, breast cancer is classified into four molecular subtypes: luminal A, luminal B, HER-2 positive, and triple-negative breast cancer (TNBC). This classification plays an important role in guiding treatment decisions, both in the adjuvant and neoadjuvant setting. In recent years, advances in breast cancer oncology has led to the development and implementation of genetic profiling tools that help assess recurrence risk and predict the potential benefit of chemotherapy. However, significant challenges remain. Resistance to therapy, disease recurrence, and the lack of successful targeted therapies for TNBC highlight the urgent need for further research into the molecular pathobiology of breast cancer. From a surgical perspective, some of the most promising opportunities lie in applying molecular tools to enhance cancer diagnosis and optimize treatment strategies. In this Special Issue, we welcome the submission of both original research and review articles focused on molecular and translational aspects of breast cancer carcinogenesis and treatments.

Guest Editor

Dr. Ioanna Akrida

Department of Surgery, University Hospital of Patras, Patras, Greece

Deadline for manuscript submissions

30 June 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/248652

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).